| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Lineage Cell Therapeutics, Inc. (LCTX) has 8 insiders with recent SEC Form 4 filings, including 11 buys and 1 sell. LCTX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 255.5K | $325.8K | - | |
| 10% | 75.0K | $95.6K | - | |
| Dir | 75.0K | $95.6K | - | |
| Dir | 75.0K | $95.6K | - | |
| Dir | 75.0K | $95.6K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Aug 23, 2017 | Skibsted Russell | Chief Financial Officer | Buy | 2,000 | $2.64 | $5,284.80 | New | |
| Aug 22, 2017 | Broadwood Partners, L.P.60 | Director, 10% Owner | Buy | 10,000 | $2.60 | $25,955.00 | - | |
| Aug 22, 2017 | West Michael D | Co-chief Executive Officer | Buy | 2,000 | $2.60 | $5,198.00 | +0.2% | |
| Aug 21, 2017 | Andrews Deborah J | Director | Buy | 2,396 | $2.50 | $5,990.00 | +39.9% | |
| Aug 21, 2017 | Patton Stephana Eilene | General Counsel | Buy | 7,500 | $2.58 | $19,376.25 | New | |
| Aug 21, 2017 | Mohanty Aditya P. | Co-chief Executive Officer | Buy | 7,500 | $2.50 | $18,750.00 | +9.1% | |
| Jul 31, 2017 | Kingsley Alfred D | See Remarks | Sell | 150,000 | $2.80 | $420,000.00 | -2.5% | |
| Jul 31, 2017 | Broadwood Partners, L.P.60 | Director, 10% Owner | Buy | 150,000 | $2.80 | $420,000.00 | +0.3% | |
| Jun 16, 2017 | Andrews Deborah J | Director | Buy | 2,000 | $2.95 | $5,900.00 | +50.0% | |
| May 16, 2017 | Andrews Deborah J | Director | Buy | 2,000 | $3.21 | $6,410.40 | +100.0% |